T2	eligibility 360 440	among women (BMI 25-40 kg/m2 ) following treatment for stage I-III breast cancer
T3	outcome-Measure 445 456	weight loss
T4	outcome-Measure 476 491	quality of life
T5	outcome-Measure 496 526	treatment-related side-effects
T6	control 531 541	usual care
T7	total-participants 544 550	Ninety
T8	age 573 588	55.3 Â± 8.7years
T9	intervention-participants 774 776	45
T10	control-participants 797 799	45
T12	outcome 1154 1170	mean weight loss
T13	outcome 1309 1331	reductions in fat mass
T14	outcome 1369 1388	waist circumference
T15	iv-cont-mean 1222 1229	-3.1 kg
T16	iv-cont-mean 1333 1340	-2.1 kg
T17	iv-cont-mean 1390 1397	-4.0 cm
T18	intervention 52 76	weight loss intervention
T1	outcome 1519 1528	satisfied
T11	outcome 1625 1663	adverse event (musculoskeletal injury)
T19	outcome 1736 1744	feasible
T20	outcome 1746 1756	acceptable
T21	outcome 1758 1762	safe
T22	outcome 1767 1776	effective
